Dr. Sangro Discusses Safety Profile of Nivolumab in HCC

Bruno Sangro, MD, PhD
Published: Monday, Apr 24, 2017



Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

In the CheckMate-040 trial, the PD-1 immune checkpoint inhibitor nivolumab was evaluated in patients with advanced HCC. This was the first time any PD-1 inhibitor was tested in this population, says Sangro.

Nivolumab was found to have a very similar profile to its application in other tumor types, showing very few adverse events. This was found in patients without viral infections as well as patients who have hepatitis B and hepatitis C.
 
SELECTED
LANGUAGE


Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

In the CheckMate-040 trial, the PD-1 immune checkpoint inhibitor nivolumab was evaluated in patients with advanced HCC. This was the first time any PD-1 inhibitor was tested in this population, says Sangro.

Nivolumab was found to have a very similar profile to its application in other tumor types, showing very few adverse events. This was found in patients without viral infections as well as patients who have hepatitis B and hepatitis C.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x